GlassScriptPhysician profile
James H Collier
NPI 1194182642
$2,726.82
in general payments reported to CMS, 2019-2025
22 companies · $475 in 2025
The $475 reported for 2025 was more than what 76% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $250 · 2022: $186 · 2023: $689 · 2024: $1,127 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252 · Education: $38.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.42 |
| Education | $38.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $406.75 | 2022-2025 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $372.07 | 2023-2025 | Jynarque, Abilify Asimtufii, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $326.06 | 2022-2024 | |
| Horizon Therapeutics Plc | $249.98 | 2021-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $243.14 | 2023-2025 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $238.44 | 2022-2024 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $211.79 | 2023-2025 | |
| Akebia Therapeutics INC | $152.01 | 2022-2025 | Vafseo, Auryxia |
| Mallinckrodt Hospital Products INC. | $87.03 | 2021-2023 | Acthar |
| Nxstage Medical, INC. | $85.48 | 2023 | Liberty Select Cycler, Nxstage System One |
| Lilly USA, LLC | $50.65 | 2023-2024 | Jardiance |
| Ardelyx, INC. | $44.69 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $36.99 | 2021-2023 | Ultomiris |
| Fresenius USA Marketing, INC. | $36.77 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $30.99 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $30.19 | 2025 | Purified Cortrophin Gel |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.96 | 2024 | |
| Vifor Pharma, INC. | $21.15 | 2025 | Veltassa |
| Alnylam Pharmaceuticals INC. | $20.46 | 2023 | Oxlumo |
| Teva Pharmaceuticals USA, INC. | $18.42 | 2025 | Uzedy |
| Opko Pharmaceuticals, LLC | $17.78 | 2021 | |
| Chiesi USA, INC. | $16.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Collier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.